The global brucellosis vaccine market was valued at USD 253.1 million in 2020 and is projected to reach USD 387.4 million by 2031. The market is expected to grow at a steady CAGR of 4% during the forecast period from 2021 to 2031, driven by increasing awareness of zoonotic diseases, rising livestock vaccination programs, and growing demand for animal health management solutions.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34439

Market Overview

Due to the presence of brucellosis in several susceptible production livestock systems scattered throughout Colombia, companies in the brucellosis vaccine market are making plans for its control, prevention, and eradication over the years. However, despite extensive efforts, brucellosis prevalence has fluctuated over the years without any trend of decreasing. Hence, companies are creating awareness about high impact educational and training programs required to address the disease in a comprehensive manner.

Companies in the Colombia brucellosis vaccine market are targeting vulnerable groups such as traditional smallholders, veterinary authorities, and communities in low-productivity regions for their educational and training programs.

Geographically, North America leads the market due to rigorous regulatory frameworks, while Asia-Pacific is the fastest-growing region, fueled by massive national immunization campaigns in India and China aimed at protecting their expanding dairy and meat industries.

Analysts’ Viewpoint on the Global Brucellosis Vaccine Market

Out-of-hospital care is anticipated to surge during the COVID-19 period. Stakeholders in the brucellosis vaccine market are increasing the availability of home healthcare providers, rehabilitation facilities, and long term care facilities. In-patient and community-based providers should review the current capacity for patients in both settings and plan for future pandemic-like situations.

Companies in the brucellosis vaccine market are scrambling to maintain robust supply chains to improve patient outcomes and meet demands. They are looking for financial aid by governments and organizing employee wellness programs to prevent & mitigate burnout, review pay & benefits compared with the industry average. Interrupted clinical research and clinical trial activities are now being conducted utilizing telehealth options wherever possible.

Analysis of Key Players in the Brucellosis Vaccine Market

The market is led by a mix of global animal health giants and regional state-owned biological institutes.

Leading companies operating in the global brucellosis vaccine market include:

• Merck Animal Health
• CEVA SANTE ANIMALE
• CZ Vaccines
• Colorado Serum Company
• Indian Immunologicals Ltd.
• Hester Biosciences Limited
• Veterinary Technologies Corporation
• Fivet Animal Health
• Jordan Bio-industries Center
• Laboratories Tornel

These players are focusing on Combination Vaccines that protect against brucellosis alongside other livestock diseases like Foot-and-Mouth Disease (FMD), reducing the logistical burden for farmers and government workers.

Recent Developments in Brucellosis Vaccine Market

• April 2026: A coalition of researchers in the Asia-Pacific region launched a pilot program for a “Digital Vaccination Certificate” system, using blockchain to track brucellosis immunization status across cross-border livestock trade routes.
• January 2026: India’s National Animal Disease Control Programme (NADCP) entered its final phase, aiming for 100% vaccination coverage of female calves, supported by a specialized budget of over US$ 1.5 Billion.
• Late 2025: Strategic acquisitions in the sector, such as Zoetis’ expansion in bovine reproductive technologies, are creating more integrated health management solutions that include brucellosis prevention as a core service.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34439

Key Developments in the Brucellosis Vaccine Market

• Growth of DNA Vaccines: Expected to carve out a measurable market share by 2031 due to superior safety and DIVA compatibility.
• Thermostable Formulations: Development of vaccines that do not require continuous refrigeration for up to 30 days.
• National Eradication Mandates: Mandatory vaccination in major dairy hubs including Brazil, India, and China.
• One Health Integration: Increased funding from the WHO and FAO for zoonotic disease surveillance.
• Focus on Small Ruminants: Rising demand for Rev-1 vaccines to curb B. melitensis outbreaks in sheep and goat herds.

Key Player Strategies

🛡️ DIVA-First R&D

Prioritizing vaccine strains that allow diagnostic tests to accurately differentiate between infected and vaccinated livestock.

🌍 Emerging Market Localization

Establishing manufacturing plants in Africa and South Asia to lower costs and bypass cold-chain logistics.

🤝 Government Tenders & PPPs

Securing long-term contracts through massive national livestock health programs.

🐄 Combination Therapy Development

Packaging brucellosis antigens with other core livestock vaccines to improve farm-level compliance.

📊 Digital Traceability

Integrating vaccine delivery with ear-tagging and digital databases to provide proof-of-vaccination for exporters.

Challenges

• Human Infection Risks: Safety concerns regarding accidental self-inoculation by veterinarians with live attenuated strains (e.g., S19).
• Diagnostic Interference: Older vaccines (S19) causing false positives in screening tests, hampering trade.
• Fragmented Veterinary Services: Limited access to professional veterinary care in rural and nomadic regions.
• Cold Chain Vulnerability: Maintaining the “cold link” in remote, high-temperature environments.

Opportunities

🥛 Dairy Herd Modernization

Rising demand for disease-free high-yield dairy cows in developing markets.

🧪 Subunit & Recombinant Vaccines

High-growth potential for non-living vaccine alternatives that eliminate safety risks to humans.

🌾 Smallholder Farmer Initiatives

Opportunity to develop low-cost, easy-to-administer oral or nasal vaccines for rural communities.

📈 Livestock Export Certification

Growing requirement for biometric/digital proof of brucellosis-free status for international trade.

🛡️ Biosecurity Consulting

Integrated services that combine vaccination with on-farm hygiene and testing protocols.

Market Segmentation

• By Type
  • RB51 Vaccine
  • S19 Vaccine
  • Others
• By Vaccine Type
  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine
• By Application
  • Cattle
  • Sheep & Goat
  • Others
• By Distribution Channel
  • Veterinary Hospitals & Clinics
  • Retail Channels
  • Others
•  By Region

• North America
• Latin America
• Europe
• Latin America
• Middle East & Africa

Conclusion

The brucellosis vaccine market is evolving from a traditional livestock maintenance sector into a sophisticated “One Health” security pillar. Through 2036, the transition toward DNA-based and thermostable vaccines will be the primary driver, enabling mass eradication efforts that were previously limited by diagnostic confusion and cold-chain failures.

As emerging economies prioritize food security and human health, the brucellosis vaccine market will remain a fundamental component of the global agricultural economy.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=34439&ltype=S

FAQs

• What is the total market worth of brucellosis vaccine market?

Brucellosis vaccine market to reach valuation of US$ 387.4 Mn by 2031

• What is the anticipated CAGR of the brucellosis vaccine market in the forecast period?

Brucellosis vaccine market is projected to grow at a CAGR of 4% during 2021-2031

• What are the key driving factors for the growth of the brucellosis vaccine market?

Brucellosis vaccine market is driven by increase in the number of animals suffering from brucellosis

• Which is the rising prominent segment in the brucellosis vaccine market?

The RB51 vaccine segment dominated the global brucellosis vaccine market in 2020, and the trend is expected to continue during the forecast period.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com